DK1428023T3 - Fremgangsmåde til forudsigelse af lægemiddelsensitivitet hos patienter der lider af en inflammatorisk sygdom - Google Patents

Fremgangsmåde til forudsigelse af lægemiddelsensitivitet hos patienter der lider af en inflammatorisk sygdom

Info

Publication number
DK1428023T3
DK1428023T3 DK02762680T DK02762680T DK1428023T3 DK 1428023 T3 DK1428023 T3 DK 1428023T3 DK 02762680 T DK02762680 T DK 02762680T DK 02762680 T DK02762680 T DK 02762680T DK 1428023 T3 DK1428023 T3 DK 1428023T3
Authority
DK
Denmark
Prior art keywords
inflammatory disease
expression profile
sample
patients suffering
drug sensitivity
Prior art date
Application number
DK02762680T
Other languages
English (en)
Inventor
Hakon Hakonarson
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Application granted granted Critical
Publication of DK1428023T3 publication Critical patent/DK1428023T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02762680T 2001-09-06 2002-09-02 Fremgangsmåde til forudsigelse af lægemiddelsensitivitet hos patienter der lider af en inflammatorisk sygdom DK1428023T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/947,991 US7384736B2 (en) 2001-09-06 2001-09-06 Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
PCT/IB2002/003613 WO2003021261A2 (en) 2001-09-06 2002-09-02 Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease

Publications (1)

Publication Number Publication Date
DK1428023T3 true DK1428023T3 (da) 2009-01-19

Family

ID=25487094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02762680T DK1428023T3 (da) 2001-09-06 2002-09-02 Fremgangsmåde til forudsigelse af lægemiddelsensitivitet hos patienter der lider af en inflammatorisk sygdom

Country Status (9)

Country Link
US (3) US7384736B2 (da)
EP (1) EP1428023B1 (da)
JP (1) JP2005502345A (da)
AT (1) ATE406575T1 (da)
AU (1) AU2002328110B2 (da)
CA (1) CA2457476A1 (da)
DE (1) DE60228592D1 (da)
DK (1) DK1428023T3 (da)
WO (1) WO2003021261A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233651A1 (en) * 2000-04-07 2002-08-21 Ibiden Co., Ltd. Ceramic heater
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
US6893828B2 (en) * 2001-09-06 2005-05-17 Decode Genetics Ehf. Methods for producing ex vivo models for inflammatory disease and uses thereof
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
US6964850B2 (en) * 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CA2469459C (en) * 2001-12-07 2011-10-18 University Of Wyoming Methods and compositions for the diagnosis of asthma
US7655397B2 (en) * 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
US7774143B2 (en) * 2002-04-25 2010-08-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states
MXPA05005073A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
AU2003900639A0 (en) * 2003-02-12 2003-02-27 G2 Therapies Ltd Novel method of treating inflammatory diseases
WO2004107240A1 (de) * 2003-05-30 2004-12-09 Thiesen Hans-Juergen Verfahren zur beurteilung des ansprechverhaltens eines individuums auf antirheumatika
WO2004108960A2 (en) * 2003-06-09 2004-12-16 Decode Genetics Ehf. Methods for predicting drug efficacy in patients afflicted with hypertension
BRPI0416945A (pt) * 2003-11-25 2007-02-13 Novartis Ag biomarcadores para a eficácia do tratamento com hormÈnio paratiróide e calcitonina
EP1832993B1 (en) * 2006-03-06 2009-02-25 General Electric Company Automatic calibration of the sensitivity of a subject to a drug
WO2008120659A1 (ja) * 2007-03-30 2008-10-09 Oji Paper Co., Ltd. 遺伝子発現情報を用いた植物の形質を判定もしくは予測する方法
JP2010539890A (ja) 2007-09-14 2010-12-24 ユニヴァーシティ オブ サウス フロリダ 放射線治療の応答を予測するための遺伝子シグネチャー
WO2009078793A1 (en) 2007-12-14 2009-06-25 Index Pharmaceuticals Ab Method for predicting the response to a therapy
US8577620B2 (en) * 2008-03-27 2013-11-05 Gus J. Slotman Methods for assessing drug efficacy and response of patient to therapy
BRPI0906261A2 (pt) * 2008-03-31 2015-07-07 Genentech Inc "métodos de diagnóstico de um subtipo de asma em uma amostra de paciente, usos de um agente terapêutico e kits de diagnóstico de um subtipo de asma em uma amostra de paciente"
RU2578468C2 (ru) 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
US20150292012A1 (en) * 2012-10-26 2015-10-15 Case Western Reserve University Biomarkers for nod2 and/or rip2 activity related application
CN105308460A (zh) * 2013-05-02 2016-02-03 天主教大学基金会 个性化药物
CL2015001420A1 (es) * 2015-05-26 2015-10-02 Univ Chile Método ex vivo y kit predictor de respuesta a tratamiento con glucocorticoides (gc) en pacientes portadores de enfermedades inflamatorias, basado en la cuantificación de la razón de cambio de los niveles de las isoformas del receptor de gc.
ES2971091T3 (es) * 2017-08-30 2024-06-03 Bristol Myers Squibb Co Un método para supervisar las respuestas farmacodinámicas mediadas por la administración de glucocorticoides in vivo
US12191023B1 (en) 2018-03-30 2025-01-07 Flagship Pioneering Innovations Vi, Llc Systems and methods for patient targeted therapy development
CN108830040B (zh) * 2018-06-07 2021-06-15 中南大学 一种基于细胞系和药物相似性网络的药物敏感性预测方法
WO2022098882A1 (en) * 2020-11-04 2022-05-12 Massachusetts Institute Of Technology Methods for identifying drivers of immune responses using molecular expression signatures of immunomodulating agents
US12512218B2 (en) * 2021-03-12 2025-12-30 PulManage, Inc. Spirometry data systems, methods, and apparatuses
US20250188514A1 (en) * 2023-12-11 2025-06-12 King Faisal Specialist Hospital & Research Centre Method for determining the activity of a drug or drug candidate under conditions of microgravity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6801859B1 (en) 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
WO2002059367A2 (en) * 2000-11-30 2002-08-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
US20030154032A1 (en) * 2000-12-15 2003-08-14 Pittman Debra D. Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2002049634A2 (en) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
US7384736B2 (en) 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
US6893828B2 (en) * 2001-09-06 2005-05-17 Decode Genetics Ehf. Methods for producing ex vivo models for inflammatory disease and uses thereof
US20040116462A1 (en) * 2002-12-12 2004-06-17 Mitsunori Ono Indolizine compounds
WO2004108960A2 (en) * 2003-06-09 2004-12-16 Decode Genetics Ehf. Methods for predicting drug efficacy in patients afflicted with hypertension

Also Published As

Publication number Publication date
US20030134776A1 (en) 2003-07-17
WO2003021261A2 (en) 2003-03-13
US7148008B2 (en) 2006-12-12
DE60228592D1 (de) 2008-10-09
WO2003021261A3 (en) 2003-11-20
EP1428023B1 (en) 2008-08-27
JP2005502345A (ja) 2005-01-27
ATE406575T1 (de) 2008-09-15
US20030113831A1 (en) 2003-06-19
AU2002328110B2 (en) 2007-01-25
EP1428023A2 (en) 2004-06-16
US7384736B2 (en) 2008-06-10
CA2457476A1 (en) 2003-03-13
US20070054309A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
DK1428023T3 (da) Fremgangsmåde til forudsigelse af lægemiddelsensitivitet hos patienter der lider af en inflammatorisk sygdom
WO2001078652A3 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2001040517A3 (en) Evaluating and predicting clinical outcomes by gene expression analysis
IS7684A (is) Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
DK1692276T3 (da) Fremgangsmåde til induktion af udvikling og terminal differentiering af hukommelses-B-celler
AU2002327308A1 (en) Methods for evaluating pathologic conditions using extracellular rna
DK1463839T3 (da) Fremgangsmåde til detektering af human papillomavirus mRNA
GB0712154D0 (en) Method for evaluating correlations between structured and normalized information on genetic variations between humans and their personal clinical patient data
Jensen et al. Higher vascular endothelial growth factor‐C concentration in plasma is associated with increased forearm capillary filtration capacity in breast cancer‐related lymphedema
NO20043125L (no) Optisk aktive baerematerialer, fremgangsmate for fremstilling og anvendelse derav
WO2004038381A3 (en) Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2003038129A3 (en) Methods for assessing and treating leukemia
WO2004113867A3 (en) Exon analysis
WO2005006949A3 (en) Methods for predicting development of auto-immune diseases and treatment of same
DK1456404T3 (da) Fremgangsmåde til at bestemme difibrotids biologiske aktivitet
DE60327530D1 (de) Plasma urotensin und menschliche herzerkrankung
WO2005062706A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
DK1185873T3 (da) Reportermolekyler og fremgangsmåde til analyse af höjspecifitetsproteaseraktivitet
WO2004094673A8 (en) Methods for monitoring drug activities in vivo
WO2004108960A3 (en) Methods for predicting drug efficacy in patients afflicted with hypertension
ZA200502307B (en) Method for treating patients with massive blood loss
WO2004060135A3 (en) Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients
ITMI20022411A1 (it) Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
AU2003276727A1 (en) Method of haplotype-based genetic analysis for determining risk for developing insulin resistance, coronary artery disease and other phenotypes
ITMI20022743A1 (it) Metodo per la determinazione del rischio di comparsa, della presenza o del decorso di malattie tumorali.